-
Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)
Saturday, January 26, 2013 - 1:17pm | 836Read More...The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of January. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex...
-
Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)
Friday, December 28, 2012 - 12:10pm | 823Read More...The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of December. The number of shares sold short in Amgen (NASDAQ: AMGN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN) and Illumina (NASDAQ: ILMN) grew somewhat between the...
-
Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)
Wednesday, December 12, 2012 - 1:57pm | 828Read More...The short interest in biotech and emerging pharmaceutical companies was mixed again in the final two weeks of November. Shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Illumina (NASDAQ: ILMN) and Regeneron Pharmaceuticals (NASDAQ: REGN) grew somewhat between the November 15 and...
-
Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)
Monday, November 12, 2012 - 2:24pm | 844Read More...The short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of October. Shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between...
-
Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)
Thursday, October 25, 2012 - 2:09pm | 847Read More...The short interest in biotech and emerging pharmaceutical companies was mixed in the first two weeks of October. Shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG), Dendreon (NASDAQ: DNDN), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ...
-
Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)
Monday, October 15, 2012 - 6:59am | 826Read More...After largely rising in the previous period, short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of September. Shares sold short in Amgen (NASDAQ: AMGN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Illumina (NASDAQ: ILMN), Onyx...
-
Short Interest in Biotech Firms on the Rise
Monday, August 27, 2012 - 3:21pm | 571Read More...Short interest data has been released from the August 15 settlement date. Overall short sellers have continued to bet on biotech firms compared to the July 31 settlement date. A couple of notable exceptions are Alexion Pharmaceuticals (NASDAQ: ALXN) and Biogen Idec (NASDAQ: BIIB), which saw short...
-
Nine ETFs on a Roll (DRN, TQQQ, BIB, BGU)
Wednesday, May 2, 2012 - 7:09am | 1080Read More...Shares of the following exchange traded funds are more than 15% higher than 90 days ago and trading within 9% of their 52-week highs. Direxion Daily Healthcare Bull 3X Shares (NYSE: CURE) is more than 26% higher year to date but trading about where it was a month ago. The nondiversified fund...
-
Barron's Recap (3/24/12): Profiles of the World's Best CEOs
Sunday, March 25, 2012 - 11:16am | 941Read More...This weekend in Barron's online: the annual listing of the top 30 corporate chiefs, a look at Deere, International Game Technology and Alexion Pharmaceuticals, as well as growth in Latin American airlines. Cover Story “World's Best CEOs” by Andrew Bary. Barron's offers up its annual listing of...
-
Watson Pharmaceuticals Earnings Preview
Monday, July 25, 2011 - 11:13am | 647Read More...Watson Pharmaceuticals (NYSE: WPI) is scheduled to report its second-quarter 2011 results Tuesday, July 26, before the markets open. Strong first-quarter results pushed the share price to a new all-time high; can second-quarter results do the same? Analysts are looking for the drug maker to report...
-
Bank of America Gears Up For Alexion's Stock Split Aftermath
Friday, June 3, 2011 - 6:11am | 115Read More...Bank of America has published a report on Alexion Pharmaceuticals (NASDAQ: ALXN) in response to the company's recent stock split. In the report, Bank of America writes, "We adjusted our PO for the recently completed 2:1 stock split from $110 to $56, which includes minor model adjustments. We...
-
Goldman Sachs Reports on Alexion Pharmaceuticals (ALXN)
Tuesday, May 17, 2011 - 7:29am | 160Read More...Goldman Sachs commented on Alexion Pharmaceuticals (NASDAQ: ALXN) in a report released yesterday. In the report, Goldman Sachs downgraded the company, but remained somewhat positive. Goldman Sachs writes, “We remove ALXN from our Conviction Buy list and replace it with MAKO Surgical, but we...
-
Jefferies Raises PT on Alexion Pharmaceuticals To $87
Monday, April 25, 2011 - 6:58am | 27Read More...Jefferies & Company has raised the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) from $77 to $87 and maintains its Hold rating.
-
Oppenheimer Reports New Soliris Opportunities To Become Clearer In 2H11 For Alexion
Friday, March 25, 2011 - 9:08am | 167Read More...According to Oppenheimer, Alexion Pharmaceuticals' (NASDAQ: ALXN) new Soliris opportunities are likely to become clearer in 2H11. Oppenheimer reported that it has extensively reviewed potential new indications for Soliris, beyond PNH/aHUS/renal transplant, ahead of multiple proof-of-concept data...
-
Deutsche Bank Raises PT On Alexion Pharmaceuticals To $105
Friday, February 11, 2011 - 8:06am | 27Read More...Deutsche Bank has raised the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) from $79 to $105 and maintains its Buy rating.
